AOD 9604

AOD 9604 is an orally active, synthetic 16-amino acid peptide fragment derived from the C-terminal domain of human growth hormone that promotes lipolysis for obesity treatment.

Brief glance

The primary outcome is Weight Loss, but it's also used for Metabolic, Anti-Aging, Performance. This compound is considered a Peptide. It is not currently indicated as compoundable in 503A pharmacies. It is not listed under a DEA schedule.

Overview

AOD9604 is a synthetic 16-amino acid peptide fragment derived from the C-terminal domain (residues 176-191) of human growth hormone, modified with an N-terminal tyrosine for enhanced stability and oral activity. It functions as a lipolytic agent by stimulating fat breakdown (lipolysis) and inhibiting fat formation (lipogenesis), primarily through upregulation of beta-3 adrenergic receptors, without affecting IGF-1 levels or glucose metabolism. Investigated clinically for obesity treatment and potentially osteoporosis due to bone-stimulating properties on osteoblasts, it demonstrates a safety profile comparable to placebo in human trials.

AOD9604 is a synthetic 16-amino acid peptide fragment derived from the C-terminal domain of human growth hormone, specifically corresponding to amino acids 176-191 with a stabilizing tyrosine modification at the N-terminus. Originally developed as a potential anti-obesity therapeutic agent, this compound is engineered to stimulate lipolysis (fat breakdown) and inhibit lipogenesis (fat formation) without activating full growth hormone signaling pathways or elevating insulin-like growth factor 1 (IGF-1) levels. The peptide's mechanism of action involves upregulation of beta-3 adrenergic receptors, which modulate adipose tissue metabolism and fat oxidation. AOD9604 exhibits rapid plasma degradation with a half-life of approximately 4 minutes and demonstrates oral bioavailability in preclinical models; however, it is not currently approved by the FDA and remains classified primarily as a research compound for investigational use in metabolic and obesity-related applications.

Benefits

AOD 9604, a synthetic fragment of human growth hormone, promotes lipolysis by stimulating fat breakdown and inhibiting lipogenesis, aiding weight management particularly in obesity.¹,²,³,⁴,⁵ Clinical trials have demonstrated three times greater weight loss in treated participants compared to placebo, with benefits including boosted metabolism, increased calorie burn, and reduced new fat growth, while showing no significant impact on blood sugar or IGF-1 levels.²,⁵ Additional proposed effects encompass cartilage repair, bone health support for conditions like osteoarthritis, and mild anti-inflammatory activity, though these remain primarily preclinical or investigational.¹,²,³ It is not FDA-approved for clinical use and is restricted to research contexts.³

Side effects

AOD 9604 is generally well-tolerated in clinical trials, with mild side effects including headache, gastrointestinal symptoms such as nausea, diarrhea, flatulence, and abdominal pain, injection site reactions like redness, itching, or swelling, mild fatigue, and occasional nausea or bloating.⁵,⁶,⁷,⁸ These effects occurred at rates similar to placebo, with no serious adverse events, no impact on IGF-1 levels, glucose metabolism, insulin sensitivity, or immunogenicity (no anti-AOD9604 antibodies detected), and no participant withdrawals due to tolerability issues.⁵,⁷,⁸ Key safety considerations include avoiding use in pregnant or nursing women due to insufficient data, individuals with active malignancy, severe metabolic disorders like uncontrolled diabetes, or known peptide hypersensitivity, and professional athletes due to potential performance-enhancing restrictions.⁶,⁸ Higher doses may increase gastrointestinal symptoms.⁷

Mechanisms of action

AOD 9604, a synthetic peptide fragment of human growth hormone (amino acids 176-191), interacts with beta-3 adrenergic receptors on adipocyte membranes, triggering G-protein coupling and activation of adenylyl cyclase to elevate intracellular cyclic AMP (cAMP) levels.⁹,¹⁰,¹¹ This increase in cAMP activates protein kinase A (PKA), which phosphorylates and stimulates hormone-sensitive lipase to hydrolyze triglycerides into free fatty acids for oxidation and energy use.⁹,¹⁰,¹¹ Concurrently, it inhibits lipogenesis by downregulating enzymes such as fatty acid synthase and acetyl-CoA carboxylase, preventing the conversion of excess calories into new fat deposits.³,¹⁰,¹¹ Unlike full-length growth hormone, AOD 9604 does not bind GH receptors or affect IGF-1 production, confining its action to fat metabolism pathways.³,⁹ Animal studies confirm this beta-3 pathway's necessity, as its genetic absence abolishes lipolytic effects.¹⁰